Trial Profile
Multicenter Prospective Observational Study of the Outcome of Patients With Acute Myeloblastic Leukemia (AML) and Myelodysplastic Syndrome (MDS) Receiving Iron Chelation Therapy (Exjade) After Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload
- Focus Therapeutic Use
- Acronyms GREFFE
- 12 Sep 2018 New trial record